Peter MacCallum Cancer Centre

I was fortunate to present our nurse led model of care for post #CAR-T therapy at #blood2024 conference this week in Brisbane. 

A new paper, co-authored by doctors from countries including Australia, suggests that stripping the emotive word “cancer” from low-grade #prostatecancer diagnoses would reduce anxiety and unnecessary treatment. Peter Mac Urologist Dr Renu Eapen was part of the discussions, read more here: https://lnkd.in/gt6K_nFR

📢 Exciting News from the American Society of Hematology! Professor Andrew Roberts AM, a clinical haematologist at Peter Mac and the The Royal Melbourne Hospital and researcher at WEHI (Walter and Eliza Hall Institute of Medical Research), has been appointed as the next editor-in-chief of Blood, ASH's prestigious journal. Starting his five-year term in January 2025, Dr. Roberts will build on Blood’s legacy, further elevating its role in advancing haematology globally. With a strong background in leukemia and lymphoma research, including pioneering work with BCL-2 inhibitors, his leadership promises continued impact and innovation. Read more via the ASH Press Release: https://lnkd.in/gmaGvXdm

Dozens of Peter Mac researchers have been named in the top two per cent of the world's most-cited scientists based on a recently updated study published by Stanford Elsevier. Thirty-eight Peter Mac researchers were named in the top two per cent most-cited scientists across their career, while 57 Peter Mac staff were in the top two per cent of most-cited in the world for 2023. Peter Mac Acting Executive Director Cancer Research, Professor Karin (Kas) Thursky said the volume of Peter Mac researchers on the list demonstrates our global research status. “I extend my congratulations to all our researchers for this recognition. Their dedication to research not only bolsters our status as a leading cancer research institution, but also significantly impacts the lives of those affected by cancer.” Head to our website to see which of our researchers made the list - https://shorturl.at/Ucu96

Happy Halloween from Peter Mac! Our Halloween Hippo was out-and-about in her pink tutu scaring people and she found a lot of freaky friends on her journey! Wishing everyone a safe, happy, and spook-tacular Halloween! #HappyHalloween #SpookySeason

A Peter Mac-led study has provided an answer on whether taking a hormonal contraceptive further increases risk for women who already have elevated lifetime risk of #breastcancer. The study took in data from almost 5,400 women with a BRCA1 or BRCA2 gene mutation. Read about the findings: https://lnkd.in/gDJqnZ49

🌿 Peter Mac's psychology team is urging everyone to connect with nature this #NationalPsychologyWeek. This year’s theme “#psychology and the environment” is exploring the critical role that nature plays in fostering emotional resilience and mental wellness. In our fast-paced world, reconnecting with nature is a simple yet effective step towards emotional wellbeing and improved mental health - and it only takes a few minutes to reap the benefits. So put down that device and get outside (after you read the article below 😉).

We spoke to Conor, a Youth Cancer Action Board co-chair, for our 20th Anniversary last month about why youth advocacy is so important in the cancer space and some of the lessons he has taken away from his time on the Board.   #ayacancer #ayacare #youthadvocacy #ycab

Peter Mac's Associate Professor Ben Tran has presented exciting trial results at #ENASymp24 that show a new drug is producing encouraging outcomes for patients with advanced bladder cancer. Approximately eight per cent of patients with advanced metastatic bladder cancer survive for five years or longer with the trial focussing on metastatic bladder cancer patients with alterations in the FGFR3 gene - which is linked to tumour growth in 10-20% of these cases. “In this first-in-human study, we saw dose-dependent clinical activity in 10 patients, with a 50 percent overall response rate and a 100 percent disease control rate at a dose of 90mg given orally once a day in heavily pre-treated patients with metastatic bladder cancer harbouring FGFR3 mutations,” Associate Professor Tran said. “I have been involved in the development of FGFR inhibitors for many years and when I first saw the data for TYRA-300, I was very excited and knew I wanted to be involved in bringing TYRA-300 to our patients at Peter Mac.” To learn more head to our website - https://lnkd.in/gpiUqggu

A highly precise type of radiotherapy, known as "SABR", is emerging as a potential treatment for prostate cancer. Our Associate Professor David Kok - along with Dr Sathana Dushyanthen from University of Melbourne - explains in this article in The Conversation. More: https://lnkd.in/gdkbX-AV